Gabapentin's Effects on Insomnia in Patients With Recent Concussion

This study has been completed.
Information provided by (Responsible Party):
Thomas Guttuso, University at Buffalo Identifier:
First received: August 16, 2011
Last updated: June 21, 2013
Last verified: June 2013
In this open-label, pilot study the investigators will be assessing gabapentin's effects on insomnia and other concussion-related symptoms in patients with a recent concussion experiencing insomnia.

Condition Intervention Phase
Drug: Gabapentin
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by University at Buffalo:

Primary Outcome Measures:
  • Change in Insomnia Severity Index from Baseline to 1 week [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in Post Concussion Symptom Scale score from Baseline to 1 week [ Time Frame: 1 week ] [ Designated as safety issue: No ]

Enrollment: 21
Study Start Date: August 2011
Study Completion Date: June 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Gabapentin Drug: Gabapentin
300mg capsules by mouth


Ages Eligible for Study:   14 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Head trauma causing concussion with either no loss of consciousness (LOC) or LOC < 30 minutes within previous 2 weeks.
  2. ISS score at Baseline of > 14.
  3. PCSS score at Baseline > 5.
  4. If brain imaging has been checked, there was no intracerebral hemorrhage noted.
  5. Glasgow Coma Scale score of 15 at Baseline.
  6. Age of at least 14 years old.
  7. Has not taken gabapentin or pregabalin any time since concussion and has no history of intolerance to gabapentin or pregabalin.
  8. Has not taken any sleeping pills for previous 2 nights and agrees not to take any for the next 2 weeks.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01421264

United States, New York
University at Buffalo, Concussion Clinic
Buffalo, New York, United States, 14214
Sponsors and Collaborators
University at Buffalo
  More Information

Responsible Party: Thomas Guttuso, Assistant Professor, University at Buffalo Identifier: NCT01421264     History of Changes
Other Study ID Numbers: NEU3280611A 
Study First Received: August 16, 2011
Last Updated: June 21, 2013
Health Authority: Safety Monitor USA:

Keywords provided by University at Buffalo:

Additional relevant MeSH terms:
Anti-Anxiety Agents
Anti-Dyskinesia Agents
Antimanic Agents
Antiparkinson Agents
Calcium Channel Blockers
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Excitatory Amino Acid Agents
Excitatory Amino Acid Antagonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Therapeutic Uses
Tranquilizing Agents processed this record on April 27, 2016